EUCTR2006-006058-83-NL进行中（未招募）不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATX
VU Medisch Centrum0 个研究点开始时间: 2007年6月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •-Patients with histologically or cytologically confirmed, HER2/neu-negative, pre- or postmenopausal adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy. Locally recurrent disease must not be amenable to resection and/or radiotherapy with curative intent.
- •-Documented ER/PR status
- •-HER2/neu-negative disease as determined by immunohistochemistry or FISH/CISH
- •-Prior adjuvant chemotherapy is allowed provided that the last dose of chemotherapy was not within 6 months (not within 12 months if taxane-based) prior to randomization.
- •-Prior maximum cumulative dose must not exceed 360 mg/m2 for doxorubicin and 720 mg/m2 for epirubicin
- •-Female only
- •-Age ? 18 years and = 75 years
- •-ECOG PS of 0 or 1
- •-Life expectancy of ? 12 weeks
- •-Able to comply with the protocol
- •-Written informed consent (Informed Consent document to be approved by the institution’s Independent Ethics Committee [IEC]) obtained prior to any study specific screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Previous chemotherapy for locally recurrent or metastatic breast cancer
- •Prior hormonal therapy for locally recurrent or metastatic disease should have been discontinued at least 2 weeks before randomization.
- •Patients with bone metastases only are allowed provided that they are on bisphosphonate treatment > 3 months.
- •-Patients who have received adjuvant radiotherapy as part of the treatment of early breast cancer are eligible if the last fraction of radiotherapy was administered at least 6 months prior to randomization. Radiotherapy administered for the relief of metastatic bone pain is allowed prior to study entry, but
- •no more than 30% of marrow-bearing bone should have been irradiated
- •the last fraction of radiotherapy should not have been administered within 3 weeks prior to randomization.
- •-Other primary tumors within the last 5 years before inclusion, except for adequately controlled basal cell carcinoma of the skin, or carcinoma in situ of the cervix
- •-Previous or current CNS metastases. A CT or MRI of the brain must be performed within 4 weeks prior to randomization if the presence of metastases at this site is suspected.
- •-Inadequate bone marrow function: ANC: < 1.5 x 109/L, platelet count < 100 x 109/L and hemoglobin < 6 mmol/L.
- •-Inadequate liver function.
- •-History or evidence or inherited bleeding diathesis or coagulopathy with the risk of bleeding
- •-History of cerebrovascular accident
- •-Arterial or venous thrombosis = 12 months prior to registration
- •-Uncontrolled hypertension or clinically significant cardiovascular disease.
- •-Inadequate left ventricular ejection fraction at baseline.
- •-Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study treatment
研究者
相似试验
已完成
2 期
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
招募中
2 期
A randomised phase II trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in second-line treatment of advaneced or recurrent gastric cancer resistant to Docetaxel/Cisplatin/TS-1 (DCS) therapyGastric CancerJPRN-UMIN000003141Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)80
已完成
2 期
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000030892Okayama Rosai Hospital18
已完成
不适用
A study to evaluate the safety and tolerability of doxorubicin and durvalumab, in patients with advanced soft tissue sarcoma.KCT0003577Yonsei University Health System, Severance Hospital45
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30